DelveInsight's "Myofascial Pain Syndrome Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Myofascial Pain Syndrome market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Myofascial Pain Syndrome market shares of the individual therapies, a detailed current Myofascial Pain Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
The conventional definition of myofascial pain syndrome (MPS) is characterized by regional pain originating from hyperirritable spots located within taut bands of skeletal muscle, known as myofascial trigger points (MTrPs). Common etiologies of myofascial pain and dysfunction may be from direct or indirect trauma, spine pathology, exposure to cumulative and repetitive strain, postural dysfunction, and physical deconditioning. Most of the current therapies are used off-label and their safety and efficacy are not well established.
Myofascial Pain Syndrome Market Key Facts
- As per MSD Manuals, Myofascial pain syndrome (MPS) is the most common disorder affecting the temporomandibular region. It is more common among women and has a bimodal age distribution in the early 20s and around menopause.
- As per the article by Urits et al. (2020), titled “Treatment and Management of Myofascial Pain Syndrome”, patients with myofascial pain represent a large portion of the patient population and the prevalence of TrPs among patients presenting to medical clinics due to widespread pain ranges from 30-93%.
- According to Southwest Orofacial Group, Myofascial trigger points are more likely to be active in women than in men, with 55% of women having latent trigger points, compared to 45% in men.
- As per the study by Fleckenstein et al. (2019), titled “Discrepancy between prevalence and perceived effectiveness of treatment methods in myofascial pain syndrome: Results of a cross-sectional, nationwide survey”, Myofascial pain is a common dysfunction with a lifetime prevalence affecting up to 85% of the general population.
- As per the review by Gerwin et al, titled “Classification, Epidemiology, and Natural History of Myofascial Pain Syndrome”, one study that looked specifically at the prevalence of myofascial pain in a general internal medicine practice found that 31% had pain as a reason for their visit and that 30% of these patients, or 9% of the total population evaluated, had MPS.
- per the study by Bourgaize (2018) titled “A comparison of the clinical manifestation and pathophysiology of myofascial pain syndrome and fibromyalgia: implications for differential diagnosis and management”, two of the most common forms of chronic musculoskeletal pain encountered by chiropractors in daily practice include fibromyalgia (FM) and myofascial pain syndrome (MPS). The reported prevalence of MPS in clinical populations varies widely, ranging from 9–85%.
- According to Southwest Orofacial Group, Myofascial trigger points are more likely to be active in women than in men, with 55% of women having latent trigger points, compared to 45% in men.
Myofascial Pain Syndrome Market Growth
Myofascial Pain Syndrome Market Size is expected to increase during the forecast period owing to the increase in the prevalence of Myofascial Pain Syndrome, along with the expected launch of emerging therapies in the market.
The Myofascial Pain Syndrome market analysis section of the report helps to understand the current and forecasted Myofascial Pain Syndrome market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Myofascial Pain Syndrome Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
There is currently no approved drug for Myofascial Pain Syndrome treatment, so the physicians generally prescribe off-label therapies. Many of the drugs have a future in Myofascial Pain Syndrome management and treatment, but further investment and clinical trials to access their safety and efficacy are some of the current unmet needs of the MPS market.
The low investment by key industry players and lack of pipeline therapies may result in very limited growth of the Myofascial Pain Syndrome treatment market. The etiology and pathophysiology of Myofascial Pain Syndrome are still poorly understood. This might be one of the reasons for the lack of emerging therapies.
Myofascial Pain Syndrome Epidemiology Forecast
The Myofascial Pain Syndrome epidemiology section covers insights about historical and current Myofascial Pain Syndrome patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Myofascial Pain Syndrome Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Myofascial Pain Syndrome Epidemiology Segmentation
- Gender-specific Prevalence of Myofascial Pain Syndrome
- Total Prevalence of Myofascial Pain Syndrome
- Diagnosed and Treatable Cases of Myofascial Pain Syndrome
For more details, visit: Myofascial Pain Syndrome Market Growth